Showing 1081-1090 of 1484 results for "".
- Ocugen Granted FDA Orphan Drug Designation for Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-rho-mutation-associated-retinal-degenerative-disease/2478081/Ocugen announced the FDA granted the third orphan drug designation (ODD) for OCU400 in the treatment of RHO mutation-associated retinal degeneration. The RHO mutation is part of the retinitis pigmentosa (RP) group of rare, genetic disorders that involve a breakdown and loss of
- Illinois Tech Researcher Awarded $2.5 Million Grant to Prevent Vision Loss in Diabetes Patientshttps://modernod.com/news/illinois-tech-researcher-awarded-2-5-million-grant-to-prevent-vision-loss-in-diabetes-patients/2479432/Illinois Institute of Technology Professor of Biomedical Engineering Jennifer Kang-Mieler, PhD. has received a second research project grant (R01) from the National Institutes of Health to study diabetic retinopathy.
- FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 for the Treatment of Stargardt Diseasehttps://modernod.com/news/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease/2479374/Alkeus Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A developed to treat multiple retinal degenerati
- NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical for Ophthalmic Quinolone Antibiotichttps://modernod.com/news/ntc-grants-license-and-distribution-rights-in-israel-to-taro-pharmaceutical-for-ophthalmic-quinolone-antibiotic/2477905/NTC has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries. The product combines a quinolone antibiotic with an anti-inflammatory steroid
- NTC Grants Further License and Distribution Rights to Santen for Its Fixed Combination Dexamethasone With Levofloxacinhttps://modernod.com/news/ntc-grants-further-license-and-distribution-rights-to-santen-for-its-fixed-combination-dexamethasone-with-levofloxacin-in-south-east-asia/2476602/Italy-based NTC Srl and Santen Pharmaceutical announced an extension of their original agreement for Europe granting NTC’s license and distribution rights of levofloxacin+dexamethasone fixed combination eye drops to Santen. The countries covered by the exten
- Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Diseasehttps://modernod.com/news/amydis-awarded-third-grant-from-the-michael-j-fox-foundation-to-support-first-in-human-study-of-a-retinal-tracer-for-parkinsons-disease/2481198/Amydis announced it has been awarded a third grant for $1.5 million from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will support the first-in-human study of a retinal tracer targeting alpha-synuclein (ASYN) in a Prospective Randomized Open, B
- LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multicenter Clinical Trial for Treating Dry AMDhttps://modernod.com/news/lumithera-receives-notice-of-award-for-2-5-million-national-eye-institute-grant-to-support-u-s-multicenter-clinical-trial-for-treating-dry-amd/2476262/LumiThera announced that it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects
- FDA Grants Fast Track Designation to Sanofi’s Investigational Gene Therapy for Wet AMDhttps://modernod.com/news/fda-grants-fast-track-designation-to-sanofis-investigational-gene-therapy-for-wet-amd/2484142/The FDA has granted fast track designation to Sanofi's SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA&rs
- Rare Pediatric Disease Designation Granted for Ocugen's Gene Therapy for the Treatment of Stargardt Diseasehttps://modernod.com/news/rare-pediatric-disease-designation-granted-for-ocugens-gene-therapy-for-the-treatment-of-stargardt-disease/2482831/Ocugen announced that the FDA has granted Rare Pediatric Disease Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations
- Atsena Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy to Treat X-Linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-designation-gene-therapy-to-treat-x-linked-retinoschisis/2482737/Atsena Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to